Abeona Therapeutics Inc.
Pitch Summary: Abeona Therapeutics Inc. has reported a transformational FY25, driven by the FDA approval of its gene therapy Zevaskyn. Despite modest total revenue of $5.8 million, the company has reached an inflection point with its first-ever product revenue from a commercial patient. The company is investing heavily in commercialization infrastructure, and despite an operating […]
